Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 32Leukemia 21Lymphoma 15Prostatic Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, Non-Hodgkin 12Lymphoma, Follicular 10Lymphoma, Large B-Cell, Diffuse 9Leukemia, Monocytic, Acute 8Recurrence 7Lymphoma, Mantle-Cell 7Leukemia, Myelomonocytic, Acute 7Leukemia, Lymphocytic, Chronic, B-Cell 7Leukemia, Erythroblastic, Acute 7Congenital Abnormalities 7Myelodysplastic Syndromes 6Leukemia, Megakaryoblastic, Acute 6Lymphoma, Large-Cell, Immunoblastic 5Hodgkin Disease 4Burkitt Lymphoma 4Breast Neoplasms 4Blast Crisis 4Multiple Myeloma 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Biphenotypic, Acute 2HIV Infections 2Drug-Related Side Effects and Adverse Reactions 2

Interventions

Dexamethasone 338Bortezomib 188Lenalidomide 186Cyclophosphamide 166Melphalan 124Calcium Dobesilate 108daratumumab 95fludarabine phosphate 69carfilzomib 69pomalidomide 68Peripheral Blood Stem Cell Transplantation 64Filgrastim 56Thalidomide 55Busulfan 53Mycophenolic Acid 52Tacrolimus 45Granulocyte Colony-Stimulating Factor 45ixazomib 43fludarabine 42Whole-Body Irradiation 40Cyclosporine 35Etoposide 33dexamethasone acetate 31Antilymphocyte Serum 31isatuximab 29dexamethasone 21-phosphate 26Prednisone 26elotuzumab 25Biopsy 25auricularum 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Multiple Myeloma × Mitoxantrone × Clear all
NCT00005987 2017-11-29

Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
87 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00100477 2013-09-25

Use of Topotecan in Patients With Refractory Acute Leukemia

VA Office of Research and Development

Phase 2 Completed
10 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡